collection
Collections Interna

Interna

Interesting lectures for Internal Medicine Residents.

https://read.qxmd.com/read/30358811/procalcitonin-guided-antibiotic-treatment-in-patients-with-positive-blood-cultures-a-patient-level-meta-analysis-of-randomized-trials
#21
JOURNAL ARTICLE
Marc A Meier, Angela Branche, Olivia L Neeser, Yannick Wirz, Sebastian Haubitz, Lila Bouadma, Michel Wolff, Charles E Luyt, Jean Chastre, Florence Tubach, Mirjam Christ-Crain, Caspar Corti, Jens-Ulrik S Jensen, Rodrigo O Deliberato, Kristina B Kristoffersen, Pierre Damas, Vandack Nobre, Carolina F Oliveira, Yahya Shehabi, Daiana Stolz, Michael Tamm, Beat Mueller, Philipp Schuetz
BACKGROUND: Whether procalcitonin (PCT)-guided antibiotic management in patients with positive blood cultures is safe remains understudied. We performed a patient-level meta-analysis to investigate effects of PCT-guided antibiotic management in patients with bacteremia. METHODS: We extracted and analyzed individual data of 523 patients with positive blood cultures included in 13 trials, in which patients were randomly assigned to receive antibiotics based on PCT levels (PCT group) or a control group...
July 18, 2019: Clinical Infectious Diseases
https://read.qxmd.com/read/30291106/management-of-hyperglycemia-in-type-2-diabetes-2018-a-consensus-report-by-the-american-diabetes-association-ada-and-the-european-association-for-the-study-of-diabetes-easd
#22
JOURNAL ARTICLE
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication, and surgical interventions, are recommended...
December 2018: Diabetes Care
https://read.qxmd.com/read/30272503/management-of-malignant-pleural-effusions-an-official-ats-sts-str-clinical-practice-guideline
#23
JOURNAL ARTICLE
David J Feller-Kopman, Chakravarthy B Reddy, Malcolm M DeCamp, Rebecca L Diekemper, Michael K Gould, Travis Henry, Narayan P Iyer, Y C Gary Lee, Sandra Z Lewis, Nick A Maskell, Najib M Rahman, Daniel H Sterman, Momen M Wahidi, Alex A Balekian
BACKGROUND: This Guideline, a collaborative effort from the American Thoracic Society, Society of Thoracic Surgeons, and Society of Thoracic Radiology, aims to provide evidence-based recommendations to guide contemporary management of patients with a malignant pleural effusion (MPE). METHODS: A multidisciplinary panel developed seven questions using the PICO (Population, Intervention, Comparator, and Outcomes) format. The GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach and the Evidence to Decision framework was applied to each question...
October 1, 2018: American Journal of Respiratory and Critical Care Medicine
https://read.qxmd.com/read/30174448/insight-into-acinetobacter-baumannii-pathogenesis-global-resistance-mechanisms-of-resistance-treatment-options-and-alternative-modalities
#24
REVIEW
Muhammad Asif, Iqbal Ahmad Alvi, Shafiq Ur Rehman
Acinetobacter baumannii , once considered a low-category pathogen, has emerged as an obstinate infectious agent. The scientific community is paying more attention to this pathogen due to its stubbornness to last resort antimicrobials, including carbapenems, colistin, and tigecycline, its high prevalence of infections in the hospital setting, and significantly increased rate of community-acquired infections by this organism over the past decade. It has given the fear of pre-antibiotic era to the world. To further enhance our understanding about this pathogen, in this review, we discuss its taxonomy, pathogenesis, current treatment options, global resistance rates, mechanisms of its resistance against various groups of antimicrobials, and future therapeutics...
2018: Infection and Drug Resistance
https://read.qxmd.com/read/27190906/evaluation-of-vacuum-assisted-closure-therapy-for-soft-tissue-injury-in-open-musculoskeletal-trauma
#25
JOURNAL ARTICLE
Manish Raj, S P S Gill, Sunil Kumar Sheopaltan, Pulkesh Singh, Dinesh, Jasveer Sigh, Prateek Rastogi, L N Mishra
INTRODUCTION: The application of controlled levels of negative or sub atmospheric pressure for a prolonged period of time on a wound had shown to accelerate removal of excess fluid and promote hyperaemia, which eventually promote wound healing. AIM: The study was conducted with the aim to evaluate the effectiveness of Vacuum Assisted Closure (VAC) therapy for soft tissue injury in open musculoskeletal trauma. MATERIALS AND METHODS: Twenty cases of complex musculoskeletal wound involving different parts of body were included in this progressive randomized study...
April 2016: Journal of Clinical and Diagnostic Research: JCDR
https://read.qxmd.com/read/25022953/tafamidis-a-review-of-its-use-in-familial-amyloid-polyneuropathy
#26
REVIEW
Lesley J Scott
Oral tafamidis (Vyndaqel(®)) is indicated in the EU for the treatment of transthyretin (TTR) amyloidosis in adult patients with early stage symptomatic polyneuropathy to delay peripheral neurologic impairment and, in Argentina, Japan and Mexico, for delaying the peripheral neurological impairment of TTR familial amyloid polyneuropathy (TTR-FAP). It is the first disease-modifying pharmacotherapy to be approved for use in adult patients with early-stage TTR-FAP. The drug acts to kinetically stabilize the variant TTR tetramer and thereby prevent tetramer dissociation, the rate-limiting step in TTR misfolding and amyloidogenesis...
August 2014: Drugs
https://read.qxmd.com/read/22843282/tafamidis-for-transthyretin-familial-amyloid-polyneuropathy-a-randomized-controlled-trial
#27
RANDOMIZED CONTROLLED TRIAL
Teresa Coelho, Luis F Maia, Ana Martins da Silva, Marcia Waddington Cruz, Violaine Planté-Bordeneuve, Pierre Lozeron, Ole B Suhr, Josep M Campistol, Isabel Maria Conceição, Hartmut H-J Schmidt, Pedro Trigo, Jeffery W Kelly, Richard Labaudinière, Jason Chan, Jeff Packman, Amy Wilson, Donna R Grogan
OBJECTIVES: To evaluate the efficacy and safety of 18 months of tafamidis treatment in patients with early-stage V30M transthyretin familial amyloid polyneuropathy (TTR-FAP). METHODS: In this randomized, double-blind trial, patients received tafamidis 20 mg QD or placebo. Coprimary endpoints were the Neuropathy Impairment Score-Lower Limbs (NIS-LL) responder analysis (<2-point worsening) and treatment-group difference in the mean change from baseline in Norfolk Quality of Life-Diabetic Neuropathy total score (TQOL) in the intent-to-treat (ITT) population (n = 125)...
August 21, 2012: Neurology
https://read.qxmd.com/read/30145929/tafamidis-treatment-for-patients-with-transthyretin-amyloid-cardiomyopathy
#28
RANDOMIZED CONTROLLED TRIAL
Mathew S Maurer, Jeffrey H Schwartz, Balarama Gundapaneni, Perry M Elliott, Giampaolo Merlini, Marcia Waddington-Cruz, Arnt V Kristen, Martha Grogan, Ronald Witteles, Thibaud Damy, Brian M Drachman, Sanjiv J Shah, Mazen Hanna, Daniel P Judge, Alexandra I Barsdorf, Peter Huber, Terrell A Patterson, Steven Riley, Jennifer Schumacher, Michelle Stewart, Marla B Sultan, Claudio Rapezzi
BACKGROUND: Transthyretin amyloid cardiomyopathy is caused by the deposition of transthyretin amyloid fibrils in the myocardium. The deposition occurs when wild-type or variant transthyretin becomes unstable and misfolds. Tafamidis binds to transthyretin, preventing tetramer dissociation and amyloidogenesis. METHODS: In a multicenter, international, double-blind, placebo-controlled, phase 3 trial, we randomly assigned 441 patients with transthyretin amyloid cardiomyopathy in a 2:1:2 ratio to receive 80 mg of tafamidis, 20 mg of tafamidis, or placebo for 30 months...
September 13, 2018: New England Journal of Medicine
https://read.qxmd.com/read/26734952/first-european-consensus-for-diagnosis-management-and-treatment-of-transthyretin-familial-amyloid-polyneuropathy
#29
REVIEW
David Adams, Ole B Suhr, Ernst Hund, Laura Obici, Ivailo Tournev, Josep M Campistol, Michel S Slama, Bouke P Hazenberg, Teresa Coelho
PURPOSE OF REVIEW: Early and accurate diagnosis of transthyretin familial amyloid polyneuropathy (TTR-FAP) represents one of the major challenges faced by physicians when caring for patients with idiopathic progressive neuropathy. There is little consensus in diagnostic and management approaches across Europe. RECENT FINDINGS: The low prevalence of TTR-FAP across Europe and the high variation in both genotype and phenotypic expression of the disease means that recognizing symptoms can be difficult outside of a specialized diagnostic environment...
February 2016: Current Opinion in Neurology
https://read.qxmd.com/read/26734951/sixty-years-of-transthyretin-familial-amyloid-polyneuropathy-ttr-fap-in-europe-where-are-we-now-a-european-network-approach-to-defining-the-epidemiology-and-management-patterns-for-ttr-fap
#30
REVIEW
Yesim Parman, David Adams, Laura Obici, Lucía Galán, Velina Guergueltcheva, Ole B Suhr, Teresa Coelho
PURPOSE OF REVIEW: Transthyretin familial amyloid polyneuropathy (TTR-FAP) is a highly disabling, life-threatening disease characterized by progressive sensorimotor and autonomic neuropathy. The profile of the disease across Europe is inadequately understood at present. RECENT FINDINGS: The incidence and clinical presentation of TTR-FAP varies widely within Europe, with early and late-onset disease subtypes. In those regions in which the disease is endemic (Portugal, Sweden, Cyprus, and Majorca), a Val30Met substitution in the TTR gene is the predominant genetic cause, whereas in the rest of Europe, cases of TTR-FAP are mainly sporadic with genetic heterogeneity...
February 2016: Current Opinion in Neurology
https://read.qxmd.com/read/30178023/medicines-for-treatment-intensification-in-type-2-diabetes-and-type-of-insulin-in-type-1-and-type-2-diabetes-in-low-resource-settings-synopsis-of-the-world-health-organization-guidelines-on-second-and-third-line-medicines-and-type-of-insulin-for-the-control
#31
JOURNAL ARTICLE
Gojka Roglic, Susan L Norris
DESCRIPTION: The World Health Organization developed these guidelines to provide guidance on selection of medicines for treatment intensification in type 2 diabetes and on use of insulin (human or analogue) in type 1 and 2 diabetes. The target audience includes clinicians, policymakers, national diabetes program managers, and medicine procurement officers. The target population is adults with type 1 or 2 diabetes in low-resource settings in low- or high-income countries. The guidelines also apply to disadvantaged populations in high-income countries...
September 18, 2018: Annals of Internal Medicine
https://read.qxmd.com/read/30111341/effect-of-procalcitonin-guided-antibiotic-treatment-on-clinical-outcomes-in-intensive-care-unit-patients-with-infection-and-sepsis-patients-a-patient-level-meta-analysis-of-randomized-trials
#32
JOURNAL ARTICLE
Yannick Wirz, Marc A Meier, Lila Bouadma, Charles E Luyt, Michel Wolff, Jean Chastre, Florence Tubach, Stefan Schroeder, Vandack Nobre, Djillali Annane, Konrad Reinhart, Pierre Damas, Maarten Nijsten, Arezoo Shajiei, Dylan W deLange, Rodrigo O Deliberato, Carolina F Oliveira, Yahya Shehabi, Jos A H van Oers, Albertus Beishuizen, Armand R J Girbes, Evelien de Jong, Beat Mueller, Philipp Schuetz
BACKGROUND: The clinical utility of serum procalcitonin levels in guiding antibiotic treatment decisions in patients with sepsis remains unclear. This patient-level meta-analysis based on 11 randomized trials investigates the impact of procalcitonin-guided antibiotic therapy on mortality in intensive care unit (ICU) patients with infection, both overall and stratified according to sepsis definition, severity, and type of infection. METHODS: For this meta-analysis focusing on procalcitonin-guided antibiotic management in critically ill patients with sepsis of any type, in February 2018 we updated the database of a previous individual patient data meta-analysis which was limited to patients with respiratory infections only...
August 15, 2018: Critical Care: the Official Journal of the Critical Care Forum
https://read.qxmd.com/read/30137444/management-of-antithrombotic-therapy-in-af-patients-presenting-with-acs-and-or-undergoing-pci-a-summary-of-the-joint-consensus-document-of-the-european-heart-rhythm-association-ehra-european-society-of-cardiology-working-group-on-thrombosis-european-association
#33
JOURNAL ARTICLE
https://read.qxmd.com/read/30113379/clinical-practice-guidelines-for-the-prevention-and-management-of-pain-agitation-sedation-delirium-immobility-and-sleep-disruption-in-adult-patients-in-the-icu
#34
JOURNAL ARTICLE
John W Devlin, Yoanna Skrobik, Céline Gélinas, Dale M Needham, Arjen J C Slooter, Pratik P Pandharipande, Paula L Watson, Gerald L Weinhouse, Mark E Nunnally, Bram Rochwerg, Michele C Balas, Mark van den Boogaard, Karen J Bosma, Nathaniel E Brummel, Gerald Chanques, Linda Denehy, Xavier Drouot, Gilles L Fraser, Jocelyn E Harris, Aaron M Joffe, Michelle E Kho, John P Kress, Julie A Lanphere, Sharon McKinley, Karin J Neufeld, Margaret A Pisani, Jean-Francois Payen, Brenda T Pun, Kathleen A Puntillo, Richard R Riker, Bryce R H Robinson, Yahya Shehabi, Paul M Szumita, Chris Winkelman, John E Centofanti, Carrie Price, Sina Nikayin, Cheryl J Misak, Pamela D Flood, Ken Kiedrowski, Waleed Alhazzani
OBJECTIVE: To update and expand the 2013 Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the ICU. DESIGN: Thirty-two international experts, four methodologists, and four critical illness survivors met virtually at least monthly. All section groups gathered face-to-face at annual Society of Critical Care Medicine congresses; virtual connections included those unable to attend. A formal conflict of interest policy was developed a priori and enforced throughout the process...
September 2018: Critical Care Medicine
https://read.qxmd.com/read/29903905/idiopathic-intracranial-hypertension-consensus-guidelines-on-management
#35
REVIEW
Susan P Mollan, Brendan Davies, Nick C Silver, Simon Shaw, Conor L Mallucci, Benjamin R Wakerley, Anita Krishnan, Swarupsinh V Chavda, Satheesh Ramalingam, Julie Edwards, Krystal Hemmings, Michelle Williamson, Michael A Burdon, Ghaniah Hassan-Smith, Kathleen Digre, Grant T Liu, Rigmor Højland Jensen, Alexandra J Sinclair
UNLABELLED: The aim was to capture interdisciplinary expertise from a large group of clinicians, reflecting practice from across the UK and further, to inform subsequent development of a national consensus guidance for optimal management of idiopathic intracranial hypertension (IIH). METHODS: Between September 2015 and October 2017, a specialist interest group including neurology, neurosurgery, neuroradiology, ophthalmology, nursing, primary care doctors and patient representatives met...
October 2018: Journal of Neurology, Neurosurgery, and Psychiatry
https://read.qxmd.com/read/30005902/refeeding-syndrome-in-adults-receiving-total-parenteral-nutrition-an%C3%A2-audit-of-practice-at-a-tertiary-uk-centre
#36
JOURNAL ARTICLE
Felipe Pantoja, Konstantinos C Fragkos, Pinal S Patel, Niamh Keane, Mark A Samaan, Ivana Barnova, Simona Di Caro, Shameer J Mehta, Farooq Rahman
BACKGROUND & AIMS: The key to preventing refeeding syndrome (RS) is identifying and appropriately managing patients at risk. We evaluated our clinical management of RS risk in patients starting total parenteral nutrition (TPN). METHODS: Patients commencing TPN at University College London Hospital between January and July 2015 were prospectively followed-up for 7-days. Eighty patients were risk assessed for RS and categorized into risk groups. High and low risk RS groups were compared focussing on the onset of biochemical features of RS (hypophosphatemia, hypokalaemia and hypomagnesemia) and initial clinical assessment...
June 2019: Clinical Nutrition
https://read.qxmd.com/read/26399868/metabolic-adaptation-to-caloric-restriction-and-subsequent-refeeding-the-minnesota-starvation-experiment-revisited
#37
RANDOMIZED CONTROLLED TRIAL
Manfred James Müller, Janna Enderle, Maryam Pourhassan, Wiebke Braun, Benjamin Eggeling, Merit Lagerpusch, Claus-Christian Glüer, Joseph J Kehayias, Dieter Kiosz, Anja Bosy-Westphal
BACKGROUND: Adaptive thermogenesis (AT) is the fat-free mass (FFM)-independent reduction of resting energy expenditure (REE) to caloric restriction (CR). AT attenuates weight loss and favors weight regain. Its variance, dynamics, and control remain obscure. OBJECTIVES: Our aims were to address the variance and kinetics of AT, its associations with body composition in the context of endocrine determinants, and its effect on weight regain. DESIGN: Thirty-two nonobese men underwent sequential overfeeding (1 wk at +50% of energy needs), CR (3 wk at -50% of energy needs), and refeeding (2 wk at +50% of energy needs)...
October 2015: American Journal of Clinical Nutrition
https://read.qxmd.com/read/30077690/clinical-approach-to-the-therapy-of-asthma-copd-overlap
#38
REVIEW
Diego J Maselli, Megan Hardin, Stephanie A Christenson, Nicola A Hanania, Craig P Hersh, Sandra G Adams, Antonio Anzueto, Jay I Peters, MeiLan K Han, Fernando J Martinez
Over the last few years, there has been a renewed interest in patients with characteristics of both asthma and COPD. Although the precise definition of asthma-COPD overlap (ACO) is still controversial, patients with overlapping features are frequently encountered in clinical practice, and may indeed have worse clinical outcomes and increased health-care utilization than those with asthma or COPD. Therefore, there is a critical need to set a framework for the therapeutic approach of such patients. There are key distinctions in the therapy between asthma and COPD, particularly regarding the initial choice of therapy...
January 2019: Chest
https://read.qxmd.com/read/30085229/doxycycline-in-uk-guidelines-for-hospital-acquired-pneumonia-where-is-the-evidence-base
#39
LETTER
Alicia H Russell, Carolyne Horner, David M Livermore, Alasdair P MacGowan
No abstract text is available yet for this article.
November 1, 2018: Journal of Antimicrobial Chemotherapy
https://read.qxmd.com/read/30037647/continuous-low-dose-antibiotic-prophylaxis-for-adults-with-repeated-urinary-tract-infections-antic-a-randomised-open-label-trial
#40
RANDOMIZED CONTROLLED TRIAL
Holly Fisher, Yemi Oluboyede, Thomas Chadwick, Mohamed Abdel-Fattah, Catherine Brennand, Mandy Fader, Simon Harrison, Paul Hilton, James Larcombe, Paul Little, Doreen McClurg, Elaine McColl, James N'Dow, Laura Ternent, Nikesh Thiruchelvam, Anthony Timoney, Luke Vale, Katherine Walton, Alexander von Wilamowitz-Moellendorff, Jennifer Wilkinson, Ruth Wood, Robert Pickard
BACKGROUND: Repeated symptomatic urinary tract infections (UTIs) affect 25% of people who use clean intermittent self-catheterisation (CISC) to empty their bladder. We aimed to determine the benefits, harms, and cost-effectiveness of continuous low-dose antibiotic prophylaxis for prevention of recurrent UTIs in adult users of CISC. METHODS: In this randomised, open-label, superiority trial, we enrolled participants from 51 UK National Health Service organisations...
September 2018: Lancet Infectious Diseases
label_collection
label_collection
10245
2
3
2018-08-17 14:34:57
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.